Sirolimus therapy was associated with similar overall survival, yet improved steroid exposure, hyperglycemia, and serious infections. (A) Overall survival. (B) Steroid dose from baseline through day 365 (median, IQR). (C) Hyperglycemia status (random glucose >200 mg/dL or fasting level >126 mg/dL, or use of diabetes medications) at day 28 and 56. (D) Cumulative incidence of serious (grade II-III) infections.